{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-304330","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.272822+00:00","generated_at":"2026-06-21T04:51:29.037571+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kymera reports positive KT-474 Phase 1 data; Sanofi advances to Phase 2; oncology programs show target knockdown","bullets":["KT-474 achieved >90% IRAK4 degradation in blood and skin; cytokine inhibition up to 98% in AD and 84% in HS; no serious AEs.","Sanofi committed to Phase 2 trials for KT-474 in HS and AD, with first study starting in 2023.","KT-413 (IRAKIMiD) showed up to 100% Ikaros/Aiolos knockdown and 40% IRAK4 knockdown at dose level 2; no DLTs.","KT-333 (STAT3) showed mean 66% STAT3 degradation (up to 86%) in PBMC at dose level 1; dose level 2 enrolling.","FDA cleared IND for KT-253 (MDM2 degrader); Phase 1 planned for early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-304330","json":"https://secwatch.observer/filing/0001193125-22-304330.json","markdown":"https://secwatch.observer/filing/0001193125-22-304330.md","text":"https://secwatch.observer/filing/0001193125-22-304330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312522304330/0001193125-22-304330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312522304330/d429465d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:51:29.037571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}